File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The battle against nasopharyngeal cancer

TitleThe battle against nasopharyngeal cancer
Authors
KeywordsEarly detection
Epidemiology
Nasopharyngeal carcinoma
Prognostication
Treatment
Issue Date2012
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radonc
Citation
Radiotherapy And Oncology, 2012, v. 104 n. 3, p. 272-278 How to Cite?
AbstractThis is a review of the evolving efforts to understand and combat nasopharyngeal carcinoma (NPC), a most peculiar cancer with a distinctly skewed geographic and ethnic distribution. Multifactorial etiology with dynamic interplay of genetic predisposition, Epstein-Barr virus (EBV) infection and environmental carcinogens is suggested. With changing lifestyle in Hong Kong, the age-standardized incidence rate has decreased by more than 50% during the past 30 years. The advent of megavoltage radiotherapy has transformed this once lethal cancer into one that is readily curable. Advances in technology and addition of chemotherapy have led to gratifying improvements. Overall survival exceeding 75% at 5 years could now be achieved; series using advanced technique with intensity-modulation consistently achieved excellent locoregional control. Studies are on-going to develop more potent systemic therapy for distant control. Serious late toxicities remain a serious concern demanding further improvement in radiotherapy technique and optimization of dose fractionation. Translational researches are increasingly important for the ideal goals of prevention, early detection and more accurate prognostication/prediction to work toward personalized medicine. The battle against NPC is one of the most fascinating successes in oncology, it is highly hopeful that with international collaborations and concerted efforts, we can totally conquer this cancer. © 2012 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/177398
ISSN
2015 Impact Factor: 4.817
2015 SCImago Journal Rankings: 2.654
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, AWMen_HK
dc.contributor.authorNg, WTen_HK
dc.contributor.authorChan, YHen_HK
dc.contributor.authorSze, Hen_HK
dc.contributor.authorChan, Cen_HK
dc.contributor.authorLam, THen_HK
dc.date.accessioned2012-12-18T05:07:44Z-
dc.date.available2012-12-18T05:07:44Z-
dc.date.issued2012en_HK
dc.identifier.citationRadiotherapy And Oncology, 2012, v. 104 n. 3, p. 272-278en_HK
dc.identifier.issn0167-8140en_HK
dc.identifier.urihttp://hdl.handle.net/10722/177398-
dc.description.abstractThis is a review of the evolving efforts to understand and combat nasopharyngeal carcinoma (NPC), a most peculiar cancer with a distinctly skewed geographic and ethnic distribution. Multifactorial etiology with dynamic interplay of genetic predisposition, Epstein-Barr virus (EBV) infection and environmental carcinogens is suggested. With changing lifestyle in Hong Kong, the age-standardized incidence rate has decreased by more than 50% during the past 30 years. The advent of megavoltage radiotherapy has transformed this once lethal cancer into one that is readily curable. Advances in technology and addition of chemotherapy have led to gratifying improvements. Overall survival exceeding 75% at 5 years could now be achieved; series using advanced technique with intensity-modulation consistently achieved excellent locoregional control. Studies are on-going to develop more potent systemic therapy for distant control. Serious late toxicities remain a serious concern demanding further improvement in radiotherapy technique and optimization of dose fractionation. Translational researches are increasingly important for the ideal goals of prevention, early detection and more accurate prognostication/prediction to work toward personalized medicine. The battle against NPC is one of the most fascinating successes in oncology, it is highly hopeful that with international collaborations and concerted efforts, we can totally conquer this cancer. © 2012 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radoncen_HK
dc.relation.ispartofRadiotherapy and Oncologyen_HK
dc.subjectEarly detectionen_HK
dc.subjectEpidemiologyen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPrognosticationen_HK
dc.subjectTreatmenten_HK
dc.titleThe battle against nasopharyngeal canceren_HK
dc.typeArticleen_HK
dc.identifier.emailChan, YH: chanwill@hku.hken_HK
dc.identifier.emailSze, H: henrysze@graduate.hku.hken_HK
dc.identifier.emailLam, TH: hrmrlth@hkucc.hku.hken_HK
dc.identifier.authorityChan, YH=rp01313en_HK
dc.identifier.authoritySze, H=rp01697en_HK
dc.identifier.authorityLam, TH=rp00326en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.radonc.2012.08.001en_HK
dc.identifier.pmid22938727-
dc.identifier.scopuseid_2-s2.0-84867087837en_HK
dc.identifier.hkuros212551en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84867087837&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume104en_HK
dc.identifier.issue3en_HK
dc.identifier.spage272en_HK
dc.identifier.epage278en_HK
dc.identifier.isiWOS:000310405000002-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridLee, AWM=17035384900en_HK
dc.identifier.scopusauthoridNg, WT=14825781500en_HK
dc.identifier.scopusauthoridChan, YH=22633700600en_HK
dc.identifier.scopusauthoridSze, H=23490726900en_HK
dc.identifier.scopusauthoridChan, C=27170059100en_HK
dc.identifier.scopusauthoridLam, TH=7202522876en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats